Table 2. Discounted costs, discounted quality-adjusted life expectancy (QALYs), and incremental cost-effectiveness ratios (ICERs) for the base-case analysis (screening every 3 years).
| Strategy | (Sensitivity, specificity) | Cost ($) | Incr. cost ($) | Eff. (QALYs) | Incr. eff. (QALYs) | ICER ($/QALY) | Notes |
|---|---|---|---|---|---|---|---|
| No screening | $189 | 24.685 | |||||
| Ploidy 5 cell | (0.51; 0.95) | $763 | $574 | 24.715 | 0.030 | $18 821 | Extended dominance |
| Ploidy 4 cell | (0.55; 0.95) | $767 | $577 | 24.716 | 0.032 | $18 264 | a |
| Ploidy 3 cell | (0.59; 0.93) | $878 | $110 | 24.717 | 0.001 | $132 803 | |
| Ploidy 2 cell | (0.65; 0.90) | $1044 | $167 | 24.718 | 0.001 | $148 863 | |
| Ploidy 1 cell | (0.74; 0.82) | $1482 | $438 | 24.719 | 0.001 | $418 436 | Extended dominance |
| Papanicolaou smear | (0.84; 0.88) | $1758 | $276 | 24.722 | 0.004 | $192 502 | b |
Abbreviations: Eff= effectiveness; Incr= incremental.
a
Was compared with the no screening strategy because the ploidy 5 cell strategy was dominated in an extended sense.
b
Was compared with the ploidy 2 cell strategy because the ploidy 1 cell strategy was dominated in an extended sense.